SECsense Logo

Bristol-Myers Squibb 8-K Report: Key Financial Insights from January 2025

$BMY
Form 8-K
Filed on: 2025-01-13
Source
Bristol-Myers Squibb 8-K Report: Key Financial Insights from January 2025

Based on the provided XML section of the financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Bristol-Myers Squibb Company
  • CIK Number: 0000014272
  • SEC File Number: 001-01136
  • Tax ID: 22-0790350
  • Address: Route 206 & Province Line Road, Princeton, NJ 08543
  • Contact Number: 609-252-4621
  1. Report Type:
  • Filing Type: 8-K (a report of unscheduled material events or corporate changes)
  1. Date of Report:
  • Report Date: January 13, 2025
  1. Stock Information:
  • Common Stock: $0.10 Par Value
  • Ticker Symbol: BMY (listed on NYSE)
  • 1.000% Notes due 2025: Ticker BMY25 (listed on NYSE)
  • 1.750% Notes due 2035: Ticker BMY35 (listed on NYSE)
  • Celgene Contingent Value Rights: Ticker CELG RT (listed on NYSE)
  1. Segments/Financial Instruments:
  • Common Stock: Included in the financials.
  • Debt Instruments:
    • One 1.000% Notes due 2025
    • One 1.750% Notes due 2035
  • Contingent Value Rights: Related to Celgene.
  1. Reporting Context:
  • Reporting Period: The report pertains to the date January 13, 2025, indicating it is likely a snapshot of the company's financial position or events on that specific date.

These extracted details provide a clear snapshot of Bristol-Myers Squibb's corporate identity, financial instruments, and the specifics of the 8-K filing made on January 13, 2025. This information is crucial for investors and stakeholders to understand the financial health and obligations of the company.